AbbVie Inc.

11 hours ago · fool.com

Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that beat the dividend yield of the S&P 500.

11 hours ago · 247wallst.com

With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories, and reaffirmed or raised 2026 guidance.

14 hours ago · gurufocus.com

AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR

1 day ago · prnewswire.com

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept.

3 days ago · fool.com

AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful impact on Qulipta's sales.

4 days ago · fool.com

AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net margins while offering a significantly lower valuation than many industry peers.

4 days ago · prnewswire.com

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I).

4 days ago · seekingalpha.com

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.

4 days ago · 247wallst.com

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

5 days ago · prnewswire.com

Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs).